Alkermes plc is a global biopharmaceutical company focused on neuroscience, developing and manufacturing medicines for serious mental health and addiction disorders. The company applies proprietary formulation and drug‑delivery technologies to create long-acting injectable and oral therapies.
Its commercial portfolio includes VIVITROL (naltrexone for alcohol and opioid dependence), ARISTADA and ARISTADA INITIO (long-acting aripiprazole lauroxil), and LYBALVI (olanzapine and samidorphan) for schizophrenia and bipolar I disorder. Incorporated in Ireland, Alkermes operates research, clinical, and manufacturing activities in Ireland and the United States, including a commercial manufacturing site in Wilmington, Ohio.